News & Events about Merrimack Pharmaceuticals Inc.
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK Get Rating) Director Noah G. Levy purchased 100,000 shares of the businesss stock in a transaction that occurred on Thursday, January 12th. The shares were bought at an average price of $11.90 per share, for a total transaction of $1,190,000.00. Following...
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the Company or Merrimack), announced today that its Board of Directors (the Board) has extended the Section 382 net operating loss rights plan (the Plan) that was adopted in 2019. The Plan is designed to protect the Companys ability to use its...
Thinking about buying stock in Merrimack Pharmaceuticals, Roblox, Mullen Automotive, Plug Power, or Yamana Gold? Thinking about buying stock in Merrimack Pharmaceuticals, Roblox, Mullen Automotive, Plug Power, or Yamana Gold? PR Newswire NEW YORK, Nov. 9, 2022 NEW YORK, Nov. 9, 2022 /PRNewswire...
StockNews.com started coverage on shares of Merrimack Pharmaceuticals (NASDAQ:MACK Get Rating) in a research note issued to investors on Friday. The brokerage issued a sell rating on the biopharmaceutical companys stock. Merrimack Pharmaceuticals Stock Performance MACK opened at $4.16...
StockNews.com started coverage on shares of Merrimack Pharmaceuticals (NASDAQ:MACK Get Rating) in a research note released on Thursday. The firm issued a sell rating on the biopharmaceutical companys stock. Merrimack Pharmaceuticals Price Performance Shares of NASDAQ:MACK opened at $4.10 on Thursday...